JP2020521732A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521732A5 JP2020521732A5 JP2019562380A JP2019562380A JP2020521732A5 JP 2020521732 A5 JP2020521732 A5 JP 2020521732A5 JP 2019562380 A JP2019562380 A JP 2019562380A JP 2019562380 A JP2019562380 A JP 2019562380A JP 2020521732 A5 JP2020521732 A5 JP 2020521732A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline solid
- compound
- cancer
- glutarate
- pyruvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940125904 compound 1 Drugs 0.000 claims description 60
- 239000007787 solid Substances 0.000 claims description 54
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 29
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 28
- IZGZJJKGQDJABQ-UHFFFAOYSA-N 2-hydroxyethanesulfonic acid;hydrate Chemical compound O.OCCS(O)(=O)=O IZGZJJKGQDJABQ-UHFFFAOYSA-N 0.000 claims description 20
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- -1 6,7-dimethoxyquinoline-4-yl Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 150000004682 monohydrates Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000001228 spectrum Methods 0.000 claims description 8
- 230000004580 weight loss Effects 0.000 claims description 8
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 6
- 238000004455 differential thermal analysis Methods 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 238000001757 thermogravimetry curve Methods 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229950000886 isetionate Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000002411 thermogravimetry Methods 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000011610 giant cell glioblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229930182851 human metabolite Natural products 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022127094A JP7437460B2 (ja) | 2017-05-26 | 2022-08-09 | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
| JP2024018527A JP7659097B2 (ja) | 2017-05-26 | 2024-02-09 | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511714P | 2017-05-26 | 2017-05-26 | |
| US62/511,714 | 2017-05-26 | ||
| PCT/US2018/034784 WO2018218233A1 (en) | 2017-05-26 | 2018-05-26 | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127094A Division JP7437460B2 (ja) | 2017-05-26 | 2022-08-09 | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521732A JP2020521732A (ja) | 2020-07-27 |
| JP2020521732A5 true JP2020521732A5 (enExample) | 2021-07-26 |
| JP7166292B2 JP7166292B2 (ja) | 2022-11-07 |
Family
ID=62683441
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562380A Active JP7166292B2 (ja) | 2017-05-26 | 2018-05-26 | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
| JP2022127094A Active JP7437460B2 (ja) | 2017-05-26 | 2022-08-09 | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
| JP2024018527A Active JP7659097B2 (ja) | 2017-05-26 | 2024-02-09 | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127094A Active JP7437460B2 (ja) | 2017-05-26 | 2022-08-09 | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
| JP2024018527A Active JP7659097B2 (ja) | 2017-05-26 | 2024-02-09 | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11279675B2 (enExample) |
| EP (1) | EP3630726B1 (enExample) |
| JP (3) | JP7166292B2 (enExample) |
| KR (1) | KR102611445B1 (enExample) |
| CN (1) | CN110621662B (enExample) |
| AU (1) | AU2018272088C1 (enExample) |
| CA (1) | CA3060370A1 (enExample) |
| DK (1) | DK3630726T3 (enExample) |
| EA (1) | EA039654B1 (enExample) |
| ES (1) | ES2909390T3 (enExample) |
| HU (1) | HUE058196T2 (enExample) |
| IL (1) | IL270780B2 (enExample) |
| MA (1) | MA48776A (enExample) |
| MX (1) | MX2019012505A (enExample) |
| PL (1) | PL3630726T3 (enExample) |
| PT (1) | PT3630726T (enExample) |
| SG (1) | SG11201909161PA (enExample) |
| UA (1) | UA127760C2 (enExample) |
| WO (1) | WO2018218233A1 (enExample) |
| ZA (1) | ZA201906127B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3738952A1 (en) * | 2014-02-14 | 2020-11-18 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| CA3060370A1 (en) * | 2017-05-26 | 2018-11-29 | Exelixis, Inc. | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| MY210421A (en) | 2018-01-26 | 2025-09-22 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| AU2019285066B2 (en) | 2018-06-15 | 2024-06-13 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
| PL3894012T3 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| GEAP202415849A (en) * | 2019-06-03 | 2024-03-11 | Exelixis Inc | Crystalline salt forms of kinase inhibitor |
| CN118974017A (zh) | 2022-03-01 | 2024-11-15 | 斯索恩有限公司 | 卡博替尼的l-(+)-酒石酸盐及其固体形式 |
| EP4658271A1 (en) | 2023-01-31 | 2025-12-10 | Handa Oncology, LLC | Improved cabozantinib compositions and methods of use |
| US11814356B1 (en) | 2023-03-29 | 2023-11-14 | Apotex Inc. | Salt of cabozantinib |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2392565B1 (en) * | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| RS52754B2 (sr) * | 2009-01-16 | 2022-08-31 | Exelixis Inc | Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| KR20180056807A (ko) | 2010-07-16 | 2018-05-29 | 엑셀리시스, 인코포레이티드 | C-met 조절제 약제학적 조성물 |
| JP2013537918A (ja) | 2010-09-27 | 2013-10-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
| PL2621481T5 (pl) | 2010-09-27 | 2023-03-13 | Exelixis, Inc. | Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości |
| CA2826751C (en) * | 2011-02-10 | 2021-05-18 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| JP2014513129A (ja) | 2011-05-02 | 2014-05-29 | エクセリクシス， インク． | 癌および骨癌疼痛の治療方法 |
| EP2758057B1 (en) | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| US9535315B2 (en) | 2011-10-31 | 2017-01-03 | Applied Materials, Inc. | Method of fabricating a color filter array using a multilevel structure |
| KR20140088610A (ko) | 2011-11-08 | 2014-07-10 | 엑셀리시스, 인코포레이티드 | 암을 치료하기 위한 met 및 vegf의 이중 저해제 |
| BR112014011008A2 (pt) | 2011-11-08 | 2018-06-19 | Exelixis Inc | método de quantificação de tratamento de câncer |
| CN104649969B (zh) | 2013-11-22 | 2019-02-12 | 广东东阳光药业有限公司 | 一种替尼类药物的盐及其制备方法 |
| EP3738952A1 (en) * | 2014-02-14 | 2020-11-18 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| US9815789B2 (en) * | 2014-05-23 | 2017-11-14 | Mylan Laboratories, Ltd. | Polymorphs of cabozantinib (S)-malate and cabozantinib free base |
| CN104961680B (zh) | 2014-11-07 | 2017-09-12 | 苏州晶云药物科技有限公司 | N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型 |
| CN104961681B (zh) | 2014-11-13 | 2017-06-13 | 苏州晶云药物科技有限公司 | 卡博替尼的粘酸盐及其晶型 |
| US10206916B2 (en) * | 2015-03-25 | 2019-02-19 | Sandoz Ag | Cabozantinib salts and their use as anti-cancer agents |
| ES2716633T3 (es) | 2015-03-25 | 2019-06-13 | Sandoz Ag | Formas cristalinas de fosfato de cabozantinib e hidrocloruro de cabozantinib |
| US10980792B2 (en) * | 2016-09-12 | 2021-04-20 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of Cabozantinib |
| WO2018104954A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof |
| CA3060370A1 (en) | 2017-05-26 | 2018-11-29 | Exelixis, Inc. | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
-
2018
- 2018-05-26 CA CA3060370A patent/CA3060370A1/en active Pending
- 2018-05-26 PT PT187325485T patent/PT3630726T/pt unknown
- 2018-05-26 MX MX2019012505A patent/MX2019012505A/es unknown
- 2018-05-26 KR KR1020197031409A patent/KR102611445B1/ko active Active
- 2018-05-26 AU AU2018272088A patent/AU2018272088C1/en active Active
- 2018-05-26 HU HUE18732548A patent/HUE058196T2/hu unknown
- 2018-05-26 SG SG11201909161P patent/SG11201909161PA/en unknown
- 2018-05-26 IL IL270780A patent/IL270780B2/en unknown
- 2018-05-26 PL PL18732548T patent/PL3630726T3/pl unknown
- 2018-05-26 MA MA048776A patent/MA48776A/fr unknown
- 2018-05-26 CN CN201880027861.5A patent/CN110621662B/zh active Active
- 2018-05-26 JP JP2019562380A patent/JP7166292B2/ja active Active
- 2018-05-26 EP EP18732548.5A patent/EP3630726B1/en active Active
- 2018-05-26 ES ES18732548T patent/ES2909390T3/es active Active
- 2018-05-26 EA EA201992803A patent/EA039654B1/ru unknown
- 2018-05-26 WO PCT/US2018/034784 patent/WO2018218233A1/en not_active Ceased
- 2018-05-26 DK DK18732548.5T patent/DK3630726T3/da active
- 2018-05-26 US US16/617,352 patent/US11279675B2/en active Active
- 2018-05-26 UA UAA201912198A patent/UA127760C2/uk unknown
-
2019
- 2019-09-17 ZA ZA2019/06127A patent/ZA201906127B/en unknown
-
2022
- 2022-02-09 US US17/668,098 patent/US11731941B2/en active Active
- 2022-08-09 JP JP2022127094A patent/JP7437460B2/ja active Active
-
2023
- 2023-06-29 US US18/344,267 patent/US12227481B2/en active Active
-
2024
- 2024-02-09 JP JP2024018527A patent/JP7659097B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521732A5 (enExample) | ||
| CA2925889C (en) | Hydrochloride salt form for ezh2 inhibition | |
| JP2015512942A5 (enExample) | ||
| TW201706249A (zh) | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 | |
| CN111471021A (zh) | 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法 | |
| RU2618423C2 (ru) | Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение | |
| JP2021501151A5 (enExample) | ||
| JP7621289B2 (ja) | ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用 | |
| JP2014524476A5 (enExample) | ||
| JP2017519027A (ja) | （ｓ）−６−（（１−アセチルピペリジン−４−イル）アミノ）−ｎ−（３−（３、４−ジヒドロイソキノリン−２（１ｈ）−イル）−２−ヒドロキシプロピル）ピリミジン−４−カルボキサミドの結晶塩 | |
| TW201249835A (en) | Alkyne substituted quinazoline compounds and methods of use | |
| JP5460689B2 (ja) | ４−フェニルアミノキナゾリン誘導体の多形、その調製方法、およびその使用 | |
| US9957282B2 (en) | Crystalline forms of quinolone analogs and their salts | |
| JP2026041824A (ja) | テガビビントの結晶形態、調製方法、及びその使用 | |
| JP2018537486A (ja) | キノロン類似体及びその塩の結晶形 | |
| WO2017049992A1 (zh) | Egfr激酶抑制剂及其制备方法和应用 | |
| EP3679016B1 (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| TW200808728A (en) | Method of preparing 4-halogenated quinoline intermediates | |
| HUE027375T2 (en) | Phenyl guanidine derivatives | |
| TH1901007436A (th) | รูปแบบของแข็งที่เป็นผลึกของเกลือของ n-{4-[(6,7-ไดเมทอกซีควิโนลิน-4-อิล)ออกซี]ฟีนิล}-n'-(4-ฟลูออโรฟีนิล)ไซโคลโพรเพน-1,1-ไดคาร์บอกซาไมด์, กระบวนการสำหรับการผลิต และวิธีการใช้ | |
| CN101245061B (zh) | N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物，制备方法及其用途 | |
| JP5324921B2 (ja) | 抗癌剤としてのデメチルペンクロメジン類似体とその使用 | |
| RU2802964C2 (ru) | Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида | |
| RU2024133933A (ru) | Ингибирование циклического amp-чувствительного элемент-связывающего белка (creb) | |
| JP6985137B2 (ja) | スルホンアミド化合物の結晶形 |